Meridian Bioscience, Inc. (NASDAQ:VIVO) Stake Lessened by State Board of Administration of Florida Retirement System

State Board of Administration of Florida Retirement System trimmed its stake in shares of Meridian Bioscience, Inc. (NASDAQ:VIVOGet Rating) by 40.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,777 shares of the company’s stock after selling 13,000 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Meridian Bioscience were worth $571,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Kempen Capital Management N.V. boosted its stake in Meridian Bioscience by 12.8% during the 1st quarter. Kempen Capital Management N.V. now owns 1,544,254 shares of the company’s stock valued at $40,088,000 after purchasing an additional 174,907 shares during the period. Aviva PLC bought a new stake in shares of Meridian Bioscience during the 1st quarter worth about $2,243,000. Assenagon Asset Management S.A. raised its holdings in Meridian Bioscience by 41.6% during the second quarter. Assenagon Asset Management S.A. now owns 180,170 shares of the company’s stock worth $5,481,000 after purchasing an additional 52,963 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Meridian Bioscience during the 1st quarter valued at $1,290,000. Finally, Knowledge Leaders Capital LLC acquired a new stake in shares of Meridian Bioscience in the second quarter valued at $1,370,000. 93.65% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Saturday.

Meridian Bioscience Trading Up 0.3 %

Shares of NASDAQ:VIVO opened at $32.03 on Friday. Meridian Bioscience, Inc. has a 1 year low of $17.20 and a 1 year high of $34.38. The firm has a fifty day moving average price of $32.02 and a 200 day moving average price of $30.77. The stock has a market capitalization of $1.40 billion, a PE ratio of 32.35 and a beta of 0.28. The company has a current ratio of 3.52, a quick ratio of 2.36 and a debt-to-equity ratio of 0.07.

Meridian Bioscience Company Profile

(Get Rating)

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H.

Featured Articles

Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience, Inc. (NASDAQ:VIVOGet Rating).

Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.